 COMPARISON OF PIXANTRONE RITUXIMAB WITH GEMCITABINE RITUXIMAB IN PATIENTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA OR FOLLICULAR GRADE 3 LYMPHOMA WHO HAVE RELAPSED AFTER THERAPY AND ARE NOT ELIGIBLE FOR STEM CELL TRANSPLANT: 